Senior Scientist Position Opportunity - ERA Chair in Cellular and Molecular Biology of Ageing

ERA Chair

The University of Coimbra, Portugal has been awarded an ERA Chair project (WIDESPREAD – H2020), aimed at recruiting a senior researcher (ERA Chair holder) and their research group. The research should be devoted to the study of the molecular and cellular mechanisms of ageing (and age-related diseases) using non-mammalian organisms, for example the nematode C. Elegans.

More information can be found at


Collaboration Opportunities: Glenn Center for Aging Research

The University of Michigan Glenn Center for Aging Research is accumulating tissues from male and female mice that have been treated with drugs known to extend lifespan, specifically Rapamycin, Acarbose, and 17-alpha-estradiol.  Tissues from control mice and from mice on a calorie-restricted diet are also available. 

Rapamycin, an inhibitor of mTOR, has been shown to extend lifespan by 10% - 13% in males, and by 18% - 21% in females at the dose currently being used, i.e. 14 ppm.  Many other age-sensitive traits also show slower change in rapamycin-treated mice.

Acarbose, which is thought to remain in the gastrointestinal tract and blunt post-prandial glucose surge by inhibition of starch digestion, increases median lifespan by 22% in males.  Acarbose-treated females show a much smaller, though still significant, increase in median lifespan, i.e. 5% compared to controls.

17-a-estradiol (17aE2) is a non-feminizing steroid that mimics some of the physiological effects of estrogen (17-b-estradiol) by unknown pathways that are independent of the classical estrogen receptors.  At the dose used, 14.4 ppm, 17aE2 increases median lifespan in males by 19% but does not increase lifespan of female mice.

With a few exceptions, tissues are taken from mice at age 12 or age 22 months.  All of the tissues are from genetically heterogeneous mice of the UM-HET3 stock, bred with an equal contribution of alleles from C57BL/6J, BALB/cByJ, C3H/HeJ, and DBA/2J grandparents. 

Some of these materials are already available, and others will enter the archive within the next year.  Researchers interested in discussing collaborative research projects that involve work on these tissues are asked to contact Dr. Richard Miller at

Background reading:

Miller RA et al., Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell. 2014, 13:468-77. PMID:24341993.

Harrison DE et al., Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging Cell. 2014 13:273-82. PMID: 24245565.

Wilkinson JE et al., Rapamycin slows aging in mice. Aging Cell 2012 11:675-82. PMID: 22587563.

Harrison DE et al., Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009 460:392-5. PMID: 19587680.

Miller RA et al., Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci. 2011 66:191-201. PMID: 20974732.

Nadon NL et al., Design of aging intervention studies: the NIA interventions testing program. Age (Dordr). 2008 30:187-99. PMID: 19424842.

MHRA Innovative Medicines Symposium: supporting innovative medicines development

MHRA Innovative Medicines Symposium

About the event

The MHRA Innovative Medicines Symposium offers industry professionals and academics the opportunity to hear from MHRA and experts from the Commission on Human Medicines (CHM) about regulatory considerations and support for innovative medicines and emerging technologies. Read our collection of case studies to see how we’ve supported innovation.

The event will be held at the Westminster Conference Centre London.

MHRA experts will explain how the agency supports innovation in medicines, through scientific and regulatory advice and guidance.

The symposium is designed to help you understand more about our approach to regulation for emerging technologies, including:

  • genomics
  • complex medicinal products
  • nanomedicines

It’s also an opportunity to question our expert panel and network with peers in the sector.

At the event you can:

  • discover more about the regulatory perspectives of emerging technologies and innovative medicines
  • learn about the MHRA Innovation Office, scientific advice meetings and our early access to medicines scheme
  • hear more about accessing scientific and regulatory advice from early stage development to regulatory evaluation
  • find out about early access and adaptive licensing, including the role of expert committees and the Commission of Human Medicines (CHM)
  • network with like-minded peers, share your experiences with colleagues and put questions directly to MHRA experts

Who should attend?

The event is useful for the pharmaceutical industry and academia working to develop innovative medicines, medicinal drug devices or novel manufacturing processes. It’s an opportunity to understand the range of advice MHRA can offer before submitting your licence application and covers the current regulatory considerations.


  • Early-bird tickets non-commerical: £245.00 + VAT
  • Early-bird tickets for industry: £345.00 + VAT
  • Standard rate non-commerical: £295.00 + VAT
  • Standard rate industry: £395.00 + VAT

Register for the event today!

INSIGNEO Institute for in silico Medicine- EPSRC PhD studentships


The INSIGNEO institute for in silico medicine is advertising three studentships. These projects will be part of an EPSRC funded PhD network (three projects in total) where the candidates will form, together with the supervisors and co-supervisors, a research group focused on the development and improvement of current elastic registration methods in musculoskeletal applications. 

The studentships can be viewed via the links below: 

Please note the EPSRC will cover stipend and fees only for UK students


RSS feed Subscribe to News feed